| abstract |
The present invention relates to acylated indanylamines based on the general formula (I) wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH- (C1-C3-alkyl), B is CH2 or CH- (C1-C3 -alkyl) and R 5 is an aryl or heteroaryl group, optionally substituted with the substituents listed in the description. These compounds are useful in the up-regulation of endothelial nitric oxide synthase (eNOS) and are therefore useful in the production of drugs for the treatment of cardiovascular disease, stable or unstable angina, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction , thrombosis, peripheral artery disease, endothelial atherosclerosis dysfunction, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, dysfunction of diabetic erectile dysfunction, , angiogenesis, bronchial asthma, chronic renal failure, cirrhosis of the liver, osteoporosis, limited memory capacity, limited learning capacity, or cardiovascular risk reduction in postmenopausal women or after taking contraceptives. |